source
- Vaderis gets $152M to run Phase 3 of rare bleeding disorder treatmentVaderis Therapeutics’ bet that a type of treatment developed for cancers could work for a rare blood disorder is paying off. The 13-person Swiss startup raised $152 million in a Series B to run a ...Endpoints · 21m ago↗ source
- AbCellera reports striking Phase 2 results for hot-flash treatment, shares jump 31%AbCellera Biologics announced positive Phase 2 data for its neurokinin-3 receptor antagonist aimed at relieving vasomotor symptoms such as hot flashes. The company described the results as strikin…